Mutations in the epidermal growth factor receptor gene (EGFR) are the most common and actionable molecular aberrations in non‐small cell lung cancer (NSCLC).1, 2, 3 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are effective in the treatment of advanced lung cancers harbouring EGFR mutations (EGFRm),4, 5, 6, 7 but remain expensive especially given continuous dosing for the duration that a patient benefits from these TKIs.8, 9. This evidence concerns the gene EGFR and lung cancer.